service-banner

Contact Us

Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tumor Targeting Service

Tumor targeting nucleic acid drugs have obvious targeted identification ability, which can reduce the toxic and side effects of drugs, realizing the controlled drug release. As a professional-based and research-driven global leader in drug development services, Creative Biolabs is committed to assisting clients in the development of nucleic acid drugs and providing modification design and synthesis services for tumor targeting of nucleic acid drugs.

With a rich product portfolio and leading position in the field of drug development service, Creative Biolabs strives to meet customers' various research and development needs and works with customers to accelerate the speed of drug research and development. Creative Biolabs can assist customers to customize personalized drug carriers to achieve tumor targeting of nucleic acid drugs.

We can provide the design, synthesis and modification service of the following drug carriers, but not limited to the following services:

  • FA-PEG/StNP. By reversed-phase microemulsion and cross-linking method, Creative Biolabs can assist clients in preparing the negative cross-linked starch nanoparticle (StNP). Folate - starch nanoparticle FA-PEG/StNP can be successfully prepared by modification of folate active substance (FA-PEG-NH).
    • Folic acid has stable structure, low price and no immunogenicity.
    • Folic acid has strong binding force with folic acid receptor, and can be mediated into tumor cells efficiently, so it is a target substance with great application value.
    • Creative Biolabs can connect folic acid to drug carrier by chemically bonded, such as liposome, polymer content, protein, so it can effectively realize the recognition of the antitumor drugs on tumor cell targeting and sustained release. This service can optimizes drugs to avoid damage to normal cells and improve the effect of the treatment of tumor.
    • Creative Biolabs uses starch as a natural biological material. It has good biocompatibility and no immunogenicity. Starch is very stable and does not interact with most nucleic acid drugs.
    • Starch degrades rapidly in vivo and is easy to be digested in vivo. It has high cost performance and can be widely used as drug carrier material.
    • Previous studies on Creative Biolabs showed that FA-PEG/StNP can achieve the targeting effect of tumor cells.
  • FA-CTS. Creative Biolabs can provide synthesis service of folate-coupled chitosan (FA-CTS) nanoparticles and validation service of tumor cells targeted. FA-CTS is prepared by the reaction of folic acid active ester with the amino group on chitosan molecule to form a stable amide bond. The target nucleic acid drugs are prepared into FA-CTS/drug nanoparticles by using the characteristics of chitosan with positive charge in partial acidic solution and its ability to agglutinate with anions under the action of high-speed magnetic agitation.
    • Chitosan (CTS) is a kind of natural biodegradable polymer material with good biocompatibility and biodegradability. Chitosan can be used as drug carrier materials for tumor targeting by physical or chemical modification.
    • Previous studies on Creative Biolabs showed that FA-CTS can achieve the targeting effect of tumor cells.
  • Hyaluronic acid nanoparticles. With deoxycholic acid as the hydrophobic group, Creative Biolabs provides the preparation service of hydrophobic modified hyaluronic acid-deoxycholic acid coupling. The analysis on the self-assembly behavior of this amphiphilic molecule in aqueous solution can be provided. Creative Biolabs can provide the preparation service of drug-loaded hyaluronic acid nanoparticles using target nucleic acid drugs as model drugs.

References

  1. Kim JH, et al. Hyaluronic Acid-Based Nanomaterials for Cancer Therapy. Polymers (Basel). 2018; 10(10):1133.
  2. Li L, et al. Fabrication of self-assembled folate-biotin-quaternized starch nanoparticles as co-carrier of doxorubicin and siRNA. J Biomater Appl. 2017; 32(5):587-597.

*For Research Use Only. Not for use in diagnostic procedures.

Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.